Topical treatment of venous ulcer with fibrin stabilizing factor: Experimental investigation of effects on vascular permeability

Vasa - Journal of Vascular Diseases

Volumn 28, Issue 3, 1999, Pages 160-163

  Wozniak, G ^a   Noll, T ^b   Brunner, U ^b   Hehrlein, F W ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b NONE

Author keywords

Albumin flux; Barrier function; Endothelial permeability; Factor XIII; Venous ulcer

Indexed keywords

BLOOD CLOTTING FACTOR 13 CONCENTRATE; HUMAN ALBUMIN; TRYPAN BLUE;

ANIMAL CELL; AORTA; ARTERY ENDOTHELIUM; ARTICLE; BLOOD VESSEL PERMEABILITY; COMPARTMENT MODEL; CONTROLLED STUDY; ENDOTHELIUM CELL; FILTER; MONOLAYER CULTURE; NONHUMAN; SERUM; SWINE; TOPICAL DRUG ADMINISTRATION; ULCER;

EID: 0032774376     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526.28.3.160     Document Type: Article

References (30)

1. Backhouse CM, Blair SD, Savage AP, Walton J, Mccollum CN. Controlled trail of occlusive dressings in healing chronic venous ulcers. Br J Surg 1988; 74: 626-627.
2. Barry EL, Mosher DF. Factor XIII crosslinking of fibronectin al cellular matrix assembly sites. J Biol Chem 1988; 263: 10464-10469.
3. Bolliger A. Konservative Therapie der chronisch venösen Insuffizienz. In: Klüken N (ed) Die akute und chronisch venöse Insuffizienz: Schattauer Verlag Stuttgart, 1990, 262-267.
4. Bollinger A, Herrig I, Fischer M, Hoffmann U, Franzeck UK. Intravital capillaroscopy in patients with chronic venous insufficiency and lymphoedema: Relevance to Daflon 500 mg. Int J Microcirc 1995, 15 (suppl 1), 41-44.
5. Brown GL, Nanney LB, Griffen J, Cramer AB, Yancey JM, Curtsinger LJ 3d, Holtzin L, Schultz GS, Jurkiewicz MJ, Lynch JB. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 1989; 321: 111-112.
6. Brown LF, Lanir N, McDonagh J, Tognazzi T, Dvorak AM, Dvorak HF. Fibroblast migration in fibrin gel matrices. Am J Pathol 1993; 142: 273-283.
7. Browse NL, Burnand KG: The cause of venous ul-ceration. Lancet 1982; II: 243-245.
8. Burnand KG, Whimster I, Naidoo A, Browse NL. Pericapillary fibrin in the ulcer-bearing skin of the leg: the cause of lipodermatosclerosis and venous ulceration. Br Med J 1989; 285: 1071-1073.
9. Coleridge Smith PD, Thomas P, Scurr JH, Dormandy JA. Causes of venous ulceration: a new hypothesis. Br Med J Clin Res Ed 1988; 296: 1726-1727.
10. Cornwall JV, Dore CJ, Lewis JD. Leg ulcers: epidemiology and aetiology. Br J Surg 1986; 73: 693-696.
11. Dormandy J.A. Microcirculation in venous disorders: The role of white blood cells. Int J Microcirc 1995; 15 (suppl 1): 3-8.
12. Falanga V, Moosa H, Nemeth AJ, Alstadt SP, Eaglestein WH: Dermal pericapillary fibrin in venous disease and venous ulceration. Arch Dermatol 1987; 123: 620-623.
13. Hempel A, Noll Th, Muhs A, Piper HM. Functional antagonism between cAMP and cGMP on permeability of coronary endothelial monolayers. Am J Physiol 1996; 270: H1264-H1271.
14. Hirahara K, Shinbo K, Takahashi M, Matsuishi T. Suppressive effect of human blood coagulation factor XIII on the vascular permeability induced by anti-guinea pig endothelial cell antiserum in Guinea pigs. Thrombosis Research 1993; 71: 139-149
15. Klüken N, Zabel M: Anatomie pathologique de l'atrophie blanche. Phlébologie 1986; 39: 561-566.
16. Knighton DR, Ciresi K, Fiegel VD, Schumerth S, Butler E, Cerra F. Stimulation of repair in chronic, nonhealing, cuaneous ulcers using platelet-derived wound healing formula. Surg Gynecol Obstet 1990; 170: 56-60.
17. McDonagh J. Biochemistry of fibrin-stabilizing factor (XIII). In: McDonagh J, Seitz R, Egbring R (eds) Factor XIII. Schattauer Verlag, 1993: 2-8.
18. McDonagh PF. The microvascular pathophysiology of chronic venous insufficiency. Yale J Biol Med, 1993, 66, 27-36.
19. Noll T, Muhs A, Besselmann H, Watanabe H, Piper HM. Initiation of hyperpermeability in energy-depleted coronary endothelial monolayers. Am J Physiol 1995; 268: H1462-H1470.
20. Peschen M, Thimm C, Weyl A, Weiss JM, Kurz H, Augustin M, Simon JC, Schöpf E, Vanscheidt W. Possible role of coagulation factor XIII in the pathogenesis of venous leg ulcer. VASA 1998; 27: 89-93.
21. Piper HM, Spahr R, Mertens S, Krützfeldt A, Watanabe H. Microvascular endothelial cells from heart. In: Piper HM (ed) Cell Culture Techniques in Heart and Vessel Research. Heidelberg, Germany: Springer-Verlag 1990: 158-177.
22. Rodeheaver G, Marsh D, Edgerton MT, Edlich RF. Proteolytic enzymes as adjuncts to antimicrobial prophylaxis of contaminated wounds. Am J Surg 1975; 129: 537-544.
23. Shami SK, Sarin S, Cheatle TR, Scurr JH, Coleridge Smith PD. Venous ulcers and the superficial venous system. J Vasc Surg 1993; 17: 487-490.
24. Vanscheidt W, Halser K, Wokalek H, Niedner R, Schöpf E. Factor XIII-Deficiency in the blood of venous leg ulcer patients. Acta Derm Venerol (Stockh) 1991; 71: 55-57.
25. 2-adenosine receptor stimulation increases macromolecule permeability of coronary endothelial cells. Am J Physiol 1992; 262: H1174-1181.
26. Wolfe JH, Morland M, Browse NL. The fibrinolytic activity of varicose veins. Br JSurg 1979; 66: 185-187.
27. Wozniak G, Akintürk H, Hehrlein FW, Alemany J. Topical application of FXIII improves wound healing of ulcerative leg disease: clinical experience. Blood Coagulation and Fibrinolysis 1995; 6: 349.
28. Wozniak G, Dapper F, Alemany J. Factor XIII in ulcerative leg disease: background and preliminary clinical results. Sem Thromb Haemost 1996; 22: 445-450.
29. Wozniak G, Montag H, Alemany J. Lokalapplikation von FXIII zur Therapie kruraler Ulcerationen bei Patienten mit postthrombotischer Anamnese. Vasomed 1993; 5: 644-651.
30. Zabel M, Hettwer H. Zur Pathogenese der Atrophie blanche - histologische und elektronenmikroskopische Untersuchungen. Phlebol Proktol 1987; 16: 23-26.